Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 253

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 253
---
 period set forth in the Bid Price Requirement Letter. In addition, on October 30, 2024, the Company
received a letter from the staff at Nasdaq notifying the Company that it had not regained compliance with the continued listing requirement
to maintain a minimum market value of $50,000,000 (the “MVLS Requirement”) for its listed securities within the 180-day compliance
period granted by Nasdaq in May 2024.

94

On July 19, 2024, we also
received a letter (the “MVPHS Letter”) from Nasdaq notifying the Company that the Market Value of Publicly Held Shares (the
“MVPHS”) of the Common Stock had been below the minimum of $15,000,000 for the last 30 consecutive business days prior to
the date of the MVPHS Letter, which is required for continued listing of the Common Stock on Nasdaq (the “MVPHS Requirement”).

Each of the Bid Price Requirement
and MVLS Requirement (as defined below) deficiencies results in the commencement of delisting proceedings. However, we attended a hearing
before a Nasdaq panel (the “Nasdaq Panel”) on December 17, 2024, at which we submitted a plan to regain compliance with the
listing requirements. On January 17, 2025, the Nasdaq Panel granted the Company’s request for an extension of the deadline for regaining
compliance with Nasdaq listing requirements to April 22, 2025, subject to certain conditions (the “Nasdaq Conditions”). Pursuant
to the Nasdaq Conditions, the Company shall demonstrate compliance with the Bid Price Requirement and apply to transfer its listing to
the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also required to satisfy the $2.5 million stockholders’
equity requirement of the Nasdaq Capital Market on or prior to April 22, 2025, submit certain plans to Nasdaq and make certain disclosures.

On February 12, 2025, we
received a letter from the Nasdaq confirming that we have regained compliance with the Bid Price Requirement and we have been moved to
the Nasdaq Capital Market, as required by the Nasdaq Panel.

Regaining compliance with the Bid Price Requirement is one of the conditions
set forth by the Nasdaq Panel in its previously disclosed decision granting our request for an extension to regain compliance with certain
Nasdaq continued listing requirements until April